Huntington’s Disease Treatment Market Size, Share, By Drug, Therapy Type, Route of Administration, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035

Huntington’s Disease Treatment Market Size, Share, By Drug, Therapy Type, Route of Administration, Distribution Channel, and Region - Trends, Analysis, and Forecast till 2035

Huntington’s disease (HD) is a rare hereditary neurodegenerative disorder characterized by chorea, cognitive decline, and psychiatric disturbances. It is a genetic condition that affects the cells in brain and it’s a progressive condition that gets worse over time. Target market is driven by high burden of HD in western countries and strong product pipeline of disease-modifying therapies. Furthermore, technological advancements, which increases the efficiency and cost-effectiveness of production is also anticipated to create opportunities for growth of the global market over the forecast period.

Huntington’s Disease Treatment Market Report Highlights:

• Huntington’s disease treatment market size is expected to grow at USD 3.5 billion by 2035.
• The target market was valued at USD 1.28 billion in 2024.
• Target market is expanding at a CAGR of 11.8%.
• North America held the largest share of the market in 2024.
• Asia Pacific is projected to be the fastest-growing market in the coming years.
• The oral route segment is expected to lead the target market under route of administration.
• By drug, the tetrabenazine segment holds the largest huntington’s disease treatment market share.
• Based on therapy type, the symptomatic treatment segment is dominating the market.
• The hospital pharmacies distribution channel segment is expected to dominate the market expansion.

Key Benefits of Purchasing This Report

Gain valuable insights into revenue projections for the overall market and its sub-segments, benefiting industry leaders and new entrants.

Enhance your understanding of the competitive landscape to refine business positioning and optimize go-to-market strategies.

Stay informed on the latest trends in the Huntington’s Disease Treatment Market, including key drivers, challenges, opportunities, and barriers.

Huntington’s Disease Treatment Market Key Highlights:

In December 2024, in a recent study published in JAMA Neurology, researchers investigated whether β-blockers, which regulate the sympathetic nervous system, affect the progression and onset of Huntington’s disease. Using a large global dataset, the study evaluated the influence of β-blockers on delaying motor symptoms and slowing the progression of symptoms in individuals at various stages of Huntington’s disease.

In October 2024, Researchers from the University of Oxford have identified a key biochemical mechanism relevant to the development of Huntington’s disease. This discovery opens up the possibility of studying the disease before its clinical onset and eventually stopping its progression.

Huntington’s Disease Treatment Market Report Analysis:

For instance, according to research article by European Journal of Psychiatry, published on Elsevier, Huntington’s disease (HD) is an autosomal dominant disorder, caused by cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the huntingtin (HTT) gene on chromosome 4p. It is characterized by progressive motor, behavioral, and cognitive decline.

The prevalence of HD in Asia and Europe is about 0.4 in 100,000 people and 4–15 in 100,000 people respectively. It typically develops in adults between 30–50 years, with a life expectancy of around 20 years after diagnosis.

Although there is no cure for HD, early treatment can relieve symptoms and improve quality of life. The earliest symptoms can present as subtle psychosis, mood disturbances, or mental disabilities. Initial symptoms in HD patients are psychotic symptoms that complicate the clinical diagnosis.

Segmentation:

By Drug:

• Tetrabenazine
• Deutetrabenazine
• Valbenazine
• Others

By Therapy Type:

• Symptomatic Treatment
• Disease-Modifying Therapies
• Others

By Route of Administration:

• Oral
• Parenteral
• Others

By Distribution Channel:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Other

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• Malaysia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• GCC
• Israel
• South Africa
• Rest of Middle East & Africa

Huntingtons Disease Treatment Market Competitive Landscape

• Sun Pharmaceutical Industries Ltd.
• H. LUNDBECK A/S
• Bausch Health Companies Inc.
• Hikma Pharmaceuticals PLC
• Alnylam Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Ionis Pharmaceuticals
• LUPIN
• Neurocrine Biosciences, Inc.
• Prilenia Therapeutics B.V.
• Azevan Pharmaceuticals
• SOM BIOTECH
• UniQure NV
• ANNEXON, INC

Key Questions Answered in This Report

What was the size of the Huntington’s Disease Treatment Market in 2024?

2. What is the expected growth rate of the Huntington’s Disease Treatment Market during 2025-2035?

3. What are the key factors driving the Huntington’s Disease Treatment Market?

4. What is the breakup of the Huntington’s Disease Treatment Market based on the distribution channel?

5. What are the key regions in the Huntington’s Disease Treatment Market?

6. Who are the key players/companies in the Huntington’s Disease Treatment Market?

7. What are the drivers, restraints, and opportunities in the Huntington’s Disease Treatment Market?